<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p32" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_32{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_32{left:341px;bottom:30px;}
#t3_32{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_32{left:377px;bottom:30px;}
#t5_32{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_32{left:540px;bottom:30px;}
#t7_32{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_32{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_32{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_32{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_32{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_32{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_32{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_32{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_32{left:1107px;bottom:47px;letter-spacing:0.36px;}
#tg_32{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_32{left:36px;bottom:331px;}
#ti_32{left:46px;bottom:325px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tj_32{left:377px;bottom:325px;letter-spacing:0.12px;}
#tk_32{left:407px;bottom:325px;letter-spacing:0.13px;}
#tl_32{left:481px;bottom:325px;}
#tm_32{left:36px;bottom:316px;}
#tn_32{left:46px;bottom:310px;letter-spacing:0.11px;word-spacing:0.02px;}
#to_32{left:36px;bottom:301px;}
#tp_32{left:46px;bottom:295px;letter-spacing:0.1px;word-spacing:0.02px;}
#tq_32{left:45px;bottom:280px;letter-spacing:0.12px;}
#tr_32{left:45px;bottom:264px;letter-spacing:0.1px;word-spacing:-0.07px;}
#ts_32{left:45px;bottom:249px;letter-spacing:0.12px;}
#tt_32{left:36px;bottom:240px;}
#tu_32{left:46px;bottom:234px;letter-spacing:0.11px;word-spacing:-0.17px;}
#tv_32{left:45px;bottom:218px;letter-spacing:0.12px;}
#tw_32{left:45px;bottom:203px;letter-spacing:0.12px;word-spacing:0.01px;}
#tx_32{left:45px;bottom:188px;letter-spacing:0.13px;}
#ty_32{left:36px;bottom:179px;}
#tz_32{left:46px;bottom:173px;letter-spacing:0.11px;word-spacing:0.02px;}
#t10_32{left:45px;bottom:157px;letter-spacing:0.12px;word-spacing:0.01px;}
#t11_32{left:45px;bottom:142px;letter-spacing:0.11px;}
#t12_32{left:36px;bottom:133px;}
#t13_32{left:46px;bottom:127px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t14_32{left:45px;bottom:111px;letter-spacing:0.03px;}
#t15_32{left:110px;bottom:111px;}
#t16_32{left:432px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t17_32{left:759px;bottom:786px;letter-spacing:-0.12px;}
#t18_32{left:537px;bottom:365px;}
#t19_32{left:547px;bottom:359px;letter-spacing:-0.03px;word-spacing:0.01px;}
#t1a_32{left:546px;bottom:344px;letter-spacing:-0.04px;}
#t1b_32{left:546px;bottom:328px;letter-spacing:-0.03px;}
#t1c_32{left:827px;bottom:336px;}
#t1d_32{left:832px;bottom:328px;letter-spacing:-0.03px;}
#t1e_32{left:546px;bottom:313px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t1f_32{left:546px;bottom:298px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t1g_32{left:546px;bottom:282px;letter-spacing:-0.02px;}
#t1h_32{left:546px;bottom:267px;letter-spacing:-0.07px;word-spacing:0.03px;}
#t1i_32{left:546px;bottom:252px;letter-spacing:-0.03px;}
#t1j_32{left:546px;bottom:237px;letter-spacing:-0.02px;}
#t1k_32{left:546px;bottom:221px;letter-spacing:-0.03px;}
#t1l_32{left:546px;bottom:206px;letter-spacing:-0.06px;word-spacing:0.03px;}
#t1m_32{left:546px;bottom:191px;letter-spacing:-0.04px;}
#t1n_32{left:546px;bottom:176px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t1o_32{left:546px;bottom:160px;letter-spacing:-0.04px;}
#t1p_32{left:546px;bottom:145px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t1q_32{left:546px;bottom:130px;letter-spacing:-0.04px;word-spacing:0.01px;}
#t1r_32{left:546px;bottom:114px;letter-spacing:-0.03px;}
#t1s_32{left:36px;bottom:748px;letter-spacing:-0.1px;}
#t1t_32{left:36px;bottom:729px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t1u_32{left:36px;bottom:711px;letter-spacing:-0.1px;}
#t1v_32{left:41px;bottom:693px;}
#t1w_32{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t1x_32{left:58px;bottom:674px;letter-spacing:-0.09px;}
#t1y_32{left:63px;bottom:656px;}
#t1z_32{left:76px;bottom:656px;letter-spacing:-0.09px;}
#t20_32{left:77px;bottom:638px;letter-spacing:-0.09px;word-spacing:-0.02px;}
#t21_32{left:757px;bottom:645px;letter-spacing:-0.12px;}
#t22_32{left:77px;bottom:619px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t23_32{left:77px;bottom:601px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t24_32{left:92px;bottom:583px;letter-spacing:-0.09px;}
#t25_32{left:92px;bottom:564px;}
#t26_32{left:103px;bottom:564px;letter-spacing:-0.09px;}
#t27_32{left:77px;bottom:546px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t28_32{left:41px;bottom:528px;}
#t29_32{left:58px;bottom:528px;letter-spacing:-0.09px;}
#t2a_32{left:63px;bottom:509px;}
#t2b_32{left:76px;bottom:509px;letter-spacing:-0.09px;}
#t2c_32{left:547px;bottom:517px;}
#t2d_32{left:36px;bottom:473px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t2e_32{left:378px;bottom:480px;letter-spacing:-0.12px;}
#t2f_32{left:36px;bottom:454px;letter-spacing:-0.1px;}
#t2g_32{left:41px;bottom:436px;}
#t2h_32{left:58px;bottom:436px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t2i_32{left:41px;bottom:418px;}
#t2j_32{left:58px;bottom:418px;letter-spacing:-0.09px;}
#t2k_32{left:733px;bottom:425px;}
#t2l_32{left:36px;bottom:381px;letter-spacing:-0.09px;}
#t2m_32{left:134px;bottom:381px;letter-spacing:-0.09px;}
#t2n_32{left:224px;bottom:381px;letter-spacing:-0.1px;}
#t2o_32{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_32{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_32{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_32{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_32{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_32{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_32{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_32{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_32{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_32{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_32{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_32{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_32{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_32{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_32{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_32{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts32" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg32Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg32" style="-webkit-user-select: none;"><object width="1210" height="935" data="32/32.svg" type="image/svg+xml" id="pdf32" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_32" class="t s0_32">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_32" class="t s1_32">® </span>
<span id="t3_32" class="t s0_32">(NCCN </span>
<span id="t4_32" class="t s1_32">® </span>
<span id="t5_32" class="t s0_32">), All rights reserved. NCCN Guidelines </span>
<span id="t6_32" class="t s1_32">® </span>
<span id="t7_32" class="t s0_32">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_32" class="t s2_32">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_32" class="t s2_32">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_32" class="t s3_32">NCCN Guidelines Version 4.2024 </span>
<span id="tb_32" class="t s3_32">Cancer of the Hypopharynx </span>
<span id="tc_32" class="t s4_32">NCCN Guidelines Index </span>
<span id="td_32" class="t s4_32">Table of Contents </span>
<span id="te_32" class="t s4_32">Discussion </span>
<span id="tf_32" class="t s5_32">HYPO-A </span>
<span id="tg_32" class="t s5_32">1 OF 2 </span>
<span id="th_32" class="t s6_32">1 </span>
<span id="ti_32" class="t s7_32">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_32" class="t s8_32">and </span><span id="tk_32" class="t s7_32">Discussion</span><span id="tl_32" class="t s8_32">. </span>
<span id="tm_32" class="t s6_32">2 </span>
<span id="tn_32" class="t s8_32">Particular attention to speech and swallowing is needed during therapy. </span>
<span id="to_32" class="t s6_32">3 </span>
<span id="tp_32" class="t s8_32">For doses &gt;70 Gy, some clinicians feel that the fractionation should be </span>
<span id="tq_32" class="t s8_32">slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) </span>
<span id="tr_32" class="t s9_32">to minimize toxicity. An additional 2–3 doses can be added depending </span>
<span id="ts_32" class="t s8_32">on clinical circumstances. </span>
<span id="tt_32" class="t s6_32">4 </span>
<span id="tu_32" class="t s8_32">Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of </span>
<span id="tv_32" class="t s8_32">accelerated hypofractionated intensity-modulated radiation therapy for </span>
<span id="tw_32" class="t s8_32">early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol </span>
<span id="tx_32" class="t s8_32">Biol Phys 2010;76:1333-1338. </span>
<span id="ty_32" class="t s6_32">5 </span>
<span id="tz_32" class="t s8_32">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or </span>
<span id="t10_32" class="t s8_32">54–63 Gy with IMRT dose painting technique (dependent on dose per </span>
<span id="t11_32" class="t s8_32">fraction). </span>
<span id="t12_32" class="t s6_32">6 </span>
<span id="t13_32" class="t s7_32">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="t14_32" class="t s7_32">(SYST-A)</span><span id="t15_32" class="t s8_32">. </span>
<span id="t16_32" class="t s5_32">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t17_32" class="t sa_32">1,2 </span>
<span id="t18_32" class="t s6_32">7 </span>
<span id="t19_32" class="t s8_32">Based on published data, concurrent systemic therapy/RT most commonly uses conventional </span>
<span id="t1a_32" class="t s8_32">fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent </span>
<span id="t1b_32" class="t s8_32">cisplatin given every 3 weeks at 100 mg/m </span>
<span id="t1c_32" class="t s0_32">2 </span>
<span id="t1d_32" class="t s8_32">; 2–3 cycles of chemotherapy are used depending </span>
<span id="t1e_32" class="t s8_32">on the radiation fractionation scheme (RTOG 0129) (Ang KK, Harris J, Wheeler R, et al. </span>
<span id="t1f_32" class="t s8_32">Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med </span>
<span id="t1g_32" class="t s8_32">2010;363:24-35). When carboplatin and 5-FU are used, the recommended regimen is standard </span>
<span id="t1h_32" class="t s8_32">fractionation plus 3 cycles of chemotherapy [Bourhis J, Sire C, Graff P, et al. Concomitant </span>
<span id="t1i_32" class="t s8_32">chemoradiotherapy versus acceleration of radiotherapy with or without concomitant </span>
<span id="t1j_32" class="t s8_32">chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open- </span>
<span id="t1k_32" class="t s9_32">label phase 3 randomised trial. Lancet Oncol 2012;13:145-153]. Other fraction sizes (eg, 1.8 </span>
<span id="t1l_32" class="t s8_32">Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered </span>
<span id="t1m_32" class="t s8_32">fractionation with chemotherapy are efficacious, and there is no consensus on the optimal </span>
<span id="t1n_32" class="t s8_32">approach. In general, the use of concurrent systemic therapy/RT carries a high toxicity burden; </span>
<span id="t1o_32" class="t s8_32">multiagent chemotherapy will likely further increase the toxicity burden. For any systemic </span>
<span id="t1p_32" class="t s8_32">therapy/RT approach, close attention should be paid to published reports for the specific </span>
<span id="t1q_32" class="t s8_32">chemotherapy agent, dose, and schedule of administration. Systemic therapy/RT should be </span>
<span id="t1r_32" class="t s8_32">performed by an experienced team and should include substantial supportive care. </span>
<span id="t1s_32" class="t s5_32">DEFINITIVE: </span>
<span id="t1t_32" class="t s5_32">RT Alone </span>
<span id="t1u_32" class="t s5_32">• PTV </span>
<span id="t1v_32" class="t sb_32"></span><span id="t1w_32" class="t sc_32" data-mappings='[[94,"fi"]]'>High risk: Primary tumor and involved lymph nodes [this includes possible local subclinical inﬁltration at the primary site </span>
<span id="t1x_32" class="t s5_32">and at the high-risk level lymph node(s)] </span>
<span id="t1y_32" class="t sd_32">◊ </span><span id="t1z_32" class="t s5_32">Fractionation: </span>
<span id="t20_32" class="t s5_32">– 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks </span>
<span id="t21_32" class="t sa_32">3,4 </span>
<span id="t22_32" class="t s5_32">– 69.96 Gy (2.12 Gy/fraction) daily Monday–Friday in 6–7 weeks </span>
<span id="t23_32" class="t s5_32">– Concomitant boost accelerated RT: </span>
<span id="t24_32" class="t sc_32" data-mappings='[[40,"fi"]]'>▪ 72 Gy/6 weeks (1.8 Gy/fraction, large ﬁeld; 1.5 Gy boost as second daily fraction during last 12 treatment days) </span>
<span id="t25_32" class="t sc_32">▪ </span><span id="t26_32" class="t s5_32">66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t27_32" class="t s5_32">– Hyperfractionation: 81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily) </span>
<span id="t28_32" class="t sb_32"></span><span id="t29_32" class="t s5_32">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t2a_32" class="t sd_32">◊ </span><span id="t2b_32" class="t s5_32">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t2c_32" class="t sa_32">5 </span>
<span id="t2d_32" class="t s5_32">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t2e_32" class="t sa_32">6,7 </span>
<span id="t2f_32" class="t s5_32">• PTV </span>
<span id="t2g_32" class="t sb_32"></span><span id="t2h_32" class="t s5_32">High risk: Typically 70 Gy (2.0 Gy/fraction) </span>
<span id="t2i_32" class="t sb_32"></span><span id="t2j_32" class="t s5_32">Low to intermediate risk: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t2k_32" class="t sa_32">5 </span>
<span id="t2l_32" class="t s5_32">Either IMRT </span><span id="t2m_32" class="t s5_32">(preferred) </span><span id="t2n_32" class="t s5_32">or 3D-CRT is recommended. </span>
<span id="t2o_32" class="t se_32">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
